Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :


By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :


Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Biotech Receives FDA Approval of Second-Generation Medical Device

Streetwise Reports
0 Comments|June 13, 2019

The product's improvements and the company's commercialization approach were summarized in a Ladenburg Thalmann report.

In a June 11 research note, Ladenburg Thalmann analyst Jeffrey Cohen reported that the U.S. Food and Drug Administration approved Motus GI Holdings Inc.'s (MOTS:NASDAQ) second-generation Pure-Vu System, a device that helps facilitate the cleaning out of a poorly prepared colon during a colonoscopy.

"Achieving the approval milestone now positions the company well for full commercial launch, which we anticipate to begin in the near term," Cohen commented.

Compared to the first, this new version is 40% smaller, has a shorter set-up time of about 3.5 minutes versus 10 and is more mobile. It can be used with standard-sized colonoscopes and Motus GI's Slim Sleeve.

Cohen indicated that the company will continue to target the inpatient colonoscopy market. The improvements to the system and positive data from the REDUCE study should help facilitate product uptake.

Ladenburg expects Motus GI will initially convert practices using the first system to the second and then return to pursuing new accounts in late 2019. "We continue to be encouraged by the company's progress and anticipate strong commercial adoption in the near term," noted Cohen.

Motus GI's valuation should be comparable to that of other medical technology companies, Cohen purported. That valuation, Ladenburg's price target on the biotech, is $14.50 per share. The Buy-rated company is currently trading at around $3.42 per share.


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Disclosures from Ladenburg Thalmann, Motus GI Holdings, Inc., June 11, 2019

ANALYST CERTIFICATION: I, Jeffrey S. Cohen, attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report, provided, however, that:

The research analyst primarily responsible for the preparation of this research report has or will receive compensation based upon various factors, including the volume of trading at the firm in the subject security, as well as the firm’s total revenues, a portion of which is generated by investment banking activities.


Ladenburg Thalmann & Co. Inc. makes a market in Motus GI Holdings, Inc.


Interested in these industries and sectors?

Receive investor kits and email updates from Stockhouse and directly from these companies.

Metals & Mining

Interested in these industries and sectors?

You are already a member! Please enter your password to sign in.


No comments yet. Be first to comment!

Leave a Comment

You must be logged in to access this feature.


Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.